Moderna vaccine trial shows promising early results on Coronavirus: positive news
The manufacturer Moderna announced Monday that the first coronavirus vaccine tested on people seems to be safe and able to stimulate an immune response to infection, raising a ray of hope for a world eager to stop the epidemic.
Preliminary results, in each of the top eight people who received two doses of the test vaccine, now need to be repeated in larger tests by hundreds, then thousands, to find out if the vaccine could work in the real world. Modena’s technique, which involves genetic material from the virus called mrna, is relatively new and has not yet produced any approved vaccine.
Promising early news sent Modena stock up above 25 percent Monday afternoon, helping Wall Street to its best day in six weeks. A statement by Fed President Jerome Powell also raised shares, saying the central bank would continue to support the economy, the market.
All characteristics of Monday’s earnings in trade focused on a return to normal prospects: the Standard & Poor’s 500 indexes rose by more than 3 percent; European benchmarks rose from 4 to 6 percent, and oil prices also rose. The best results on the Standard & Poor’s 500 index were travel-related companies such as United Airlines, Expedia Group, and Marriott International Airlines.
Moderna produces the vaccine in collaboration with the National Institute of Allergy and Infectious Diseases, which is led by Dr. Anthony Fauci and has been leading clinical trials. Part of the National Institutes of Health, the agency involved in the research of other modern experimental coronavirus vaccines and Johnson received about five billion dollars from the US government to accelerate the development of vaccines.
People who were vaccinated on Monday in Moderna’s Phase I study were healthy volunteers aged 18 to 55 years. Their immune systems created antibodies that were then tested on infected cells in the laboratory and were able to prevent the virus from replicating, a key requirement for an effective vaccine. So-called neutralizing antibodies match or exceed levels found in patients recovering from virus infection in the community.
Dr. Mark J. Mulligan, director of the Range Vaccine Center, described the findings of the modernization as “very encouraging,” adding that “the number of participants is small, but seems to be a very good start.” Dr. Mulligan did not participate in the first tests but is expected to participate in later stages. Modern vaccine research.